Every minute, two individuals succumb to the consequences of Hepatitis B, despite the existence of effective treatments. The root of the issue lies in the alarming number of people who remain unaware of their infection.
The Silent Danger in the Liver
Hepatitis B often progresses without symptoms for decades. Diagnoses typically occur only at advanced stages such as cirrhosis or liver cancer. Regions like Southeast Asia and Africa bear the brunt of this silent epidemic, with Vietnam showing a prevalence of 12.3% in men and 8.8% in women.
While 90-95% of adults will spontaneously eliminate the virus after acute infection, around 5% develop a chronic form of the disease. Among those, 20-30% will eventually face severe liver complications like cirrhosis or liver cancer.
Significant Gap Between Diagnosis and Treatment
Despite the availability of effective antiviral medications such as Entecavir and Tenofovir, the diagnosis rate for Hepatitis B (HBV) remains staggeringly low. Approximately 27% of individuals living with HBV are diagnosed, and only about 4.3% receive adequate treatment. Alarmingly, there are about 4,900 new infections daily worldwide for Hepatitis B or C.
As an expert from Newcastle University succinctly puts it, “The medical options are available, but they are not reaching the patients.”
AI to Enhance Early Detection
On July 20, 2026, ALZAI Health Corp secured an exclusive global license for an AI-driven technology aimed at identifying liver risks. The system employs routine healthcare data to identify early signs of cirrhosis or metabolic dysfunction-associated steatotic liver disease (MASLD), the latter affecting over a third of the adult global population.
Modern AI systems are revolutionizing early detection in medicine but also introduce new regulatory challenges. For professionals seeking guidance, a comprehensive report is available outlining which AI systems are considered high-risk and the steps that must be taken to comply.
In parallel, a study published in the journal Hepatobiliary Communications demonstrated the potential of CT scans. Computer-assisted measurements of visceral fat and muscle mass can lead to precise predictions of impending complications from HBV-induced cirrhosis.
In clinical settings, monitoring blood values remains critical. An albumin level below 3.5 g/dL serves as an indicator for potential liver or kidney damage, particularly when accompanied by increased bilirubin or INR levels.
WHO’s Goal: Elimination by 2030
The World Health Organization (WHO) aims to eliminate viral hepatitis as a public health threat by 2030. In Africa, new infections have already been reduced by 25% between 2015 and 2024. Nonetheless, Dr. Mohamed Janabi, WHO Regional Director, urges governments to broaden access to testing and vaccination.
In Asia, significant efforts were made in July 2026:
- Vietnam: A conference on July 20 reflected on accelerated cancer prevention measures. Ho Chi Minh City plans 15 million general health checks by the year’s end.
- China: A new campaign launched in Beijing aims to close care gaps for around 75 million chronically infected individuals.
- Taiwan: A screening initiative on July 19 revealed tumors or cirrhosis in nearly 3% of participants and over half showed signs of fatty liver.
- Pakistan: A twelve-day program kicked off on July 20 in Nasirabad district, planning to test approximately 190,000 people for Hepatitis C.
The Power of Vaccination
Vaccination programs are deemed the most effective defense against Hepatitis B. Countries like Taiwan, China, and South Korea have managed to decrease liver cancer rates by 70-84% through comprehensive vaccination efforts.
Stigmatization as a Barrier to Treatment
A major challenge remains the social stigma associated with Hepatitis B. The Ghana Health Service, in July 2026, had to clarify publicly that Hepatitis B and C are not transmitted through everyday interactions like sharing meals or hugs — transmission occurs only through blood, unprotected sex, or from mother to child.
Similar challenges are noted with other chronic infections. On Zero HIV Stigma Day, July 21, 2026, it was emphasized that medical advancements alone cannot bridge the gap when patients avoid doctors due to fear of discrimination. Reports by ViiV Healthcare indicate that over half of affected individuals experience prejudice in healthcare settings, complicating efforts to implement widespread testing strategies globally.
